NPTX1 Regulates Neural Lineage Specification from Human Pluripotent Stem Cells  by Boles, Nathan C. et al.
Cell Reports
ArticleNPTX1 Regulates Neural Lineage Specification
from Human Pluripotent Stem Cells
Nathan C. Boles,1,4 Sarah E. Hirsch,1,2,4 Sheila Le,1 Barbara Corneo,1,2 Fadi Najm,3 Andrew P. Minotti,1 Qingjie Wang,1
Steven Lotz,1 Paul J. Tesar,3 and Christopher A. Fasano1,2,*
1The Neural Stem Cell Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA
2Department of Biomedical Sciences, University at Albany, New York State University of New York, Albany, NY 12201, USA
3Department of Genetics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
4These authors contributed equally to this work
*Correspondence: chrisfasano@neuralsci.org
http://dx.doi.org/10.1016/j.celrep.2014.01.026
This is anopen-access article distributed under the termsof theCreativeCommonsAttribution-NonCommercial-NoDerivativeWorks License,
which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARY
Neural induction is the first fundamental step in ner-
vous system formation.During development, a tightly
regulated nichemodulates transient extracellular sig-
nals to influence neural lineage commitment. To date,
however, the cascade of molecular events that sus-
tain these signals in humans is not well understood.
Here we show that NPTX1, a secreted protein, is
rapidly upregulated during neural induction from hu-
man pluripotent stem cells (hPSCs). By manipulating
its expression, wewere able to reduce or initiate neu-
ral lineagecommitment. A time-course transcriptome
analysis and functional assays show that NPTX1 acts
in part bybinding theNodal receptor cofactor TDGF1,
reducing both Nodal andBMP signaling. Our findings
identify one of the earliest genes expressed upon
neural induction and provide insight into human neu-
ral lineage specification.INTRODUCTION
During early embryonic development, neural tissue is derived
from the ectodermal germ layer. The sequence of events that
dictate this process requires a delicate balance and integration
of different extracellular signals. The process by which primitive,
embryonic ectodermal cells respond to neuralizing signals is
known as neural induction and marks the first step in neural
lineage commitment. Elegant experiments in lower vertebrates
revealed many molecules that are critical for nervous system in-
duction (Weinstein andHemmati-Brivanlou, 1999), and studies in
rodent models have allowed the discovery of additional genes
that are crucial for this process (Levine and Brivanlou, 2007).
Other investigations have shown that the inhibition of transform-
ing growth factor b (TGF-b) and BMP signaling pathways is the
primary mechanism that triggers neural induction in animal
models (Hemmati-Brivanlou and Melton, 1994) and human sys-
tems (Chambers et al., 2009). Although all of these studies have
been invaluable in advancing the field of neural development, the724 Cell Reports 6, 724–736, February 27, 2014 ª2014 The Authorsimmediate transcriptional events that occur downstream to
trigger and sustain neural induction have been less described,
particularly in humans. Additionally, a recent study that revealed
differences between mice and humans in expression of the neu-
ral gene PAX6 in the early developing brain highlighted the need
for more comprehensive studies in the human system (Zhang
et al., 2010).
Human pluripotent stem cell (hPSC) technology allows us to
directly assess the molecular determinants of human nervous
system induction and identify critical genetic regulators of this
process. Utilizing the knowledge gleaned from lower-animal
studies, Chambers et al. (2009) developed a defined dual
SMAD inhibition protocol for deriving neural cells from hPSCs.
This approach uses a small molecule (SB435412) to inhibit
TGF-b signaling and high concentrations of NOGGIN to inhibit
BMP signaling. In addition to that study, other groups have
also shown that the TGF-b signaling pathway (in particular, Acti-
vin/Nodal signaling) is critical for regulating the balance between
human embryonic stem cell (hESC) pluripotency and neurecto-
dermal commitment (James et al., 2005; Patani et al., 2009;
Smith et al., 2008; Vallier et al., 2004, 2009). The Nodal signaling
pathway is regulated at many levels, both extracellularly and
intracellularly, and a recent study using hESCs showed that a
SMAD-interacting protein can block Nodal signaling and in turn
cause neural differentiation (Chng et al., 2010). Extracellularly,
Nodal is regulated by a secreted protein, TDGF1 (or CRIPTO),
that works as a coreceptor to increase Nodal binding efficiency
and overall signal output (Yeo and Whitman, 2001). Blockade of
TDGF1 has been shown to induce neurectodermal differentiation
in mouse embryos (D’Andrea et al., 2008) as well as mouse
embryonic stem cells (mESCs) (Lonardo et al., 2010). Nodal
has also been shown to regulate the BMP pathway (Yeo and
Whitman, 2001), thus raising the possibility that an extracellular
Nodal pathway regulator might also have an effect on the BMP
pathway. As extracellular proteins during development play crit-
ical roles in initializing and turning down signaling pathways, the
identification of extracellular regulators of TGF-b/Nodal signaling
will provide critical information about the regulation of hESC plu-
ripotency and neural differentiation.
Using a defined neural induction protocol, we identified
NPTX1 as a secreted protein that is transiently released from
differentiating hPSCs and is critical for neural induction. Genetic
loss-of-function studies showed that hPSCs exhibit significantly
impaired neural cell induction, whereas genetic gain-of-function
results in robust, spontaneous neural differentiation. Importantly,
the result of robust differentiation could be mimicked by the
addition of NPTX1-conditioned media (CM), even in hESCs
with genetically low levels of NPTX1. Interestingly, molecular
analyses revealed that NPTX1 functions, in part, by regulating
both Nodal and BMP signaling by binding to TDGF1, a protein
that is involved in regulating pluripotency and neural differentia-
tion. Our study identifies and characterizes a molecular mecha-
nism by which hPSCs specify the neural lineage, providing
insight into the endogenous regulators of human nervous system
lineage commitment.
RESULTS
NPTX1 Reduction Leads to Impaired Neural Induction
from hPSCs
To identify novel regulators of the neural induction process, we
used a recently developed protocol to derive neural cells from
hESCs (Chambers et al., 2009), and inspected the transcriptome
throughout the differentiation time course to identify genes that
transiently increased in expression during the early stages and
were rapidly downregulated before neural characteristics ap-
peared (Fasano et al., 2010). One gene that fits this profile is
NPTX1, whose expression transiently increased early in neural
differentiation from hESCs at mRNA and protein levels (Figures
1A and 1B). This profile was verified in another hESC line, WA-
01 (Figure S1A). NPTX1 is a member of the pentraxin family of
proteins, which are secreted, form pentamers and decamers,
and can bind to a wide variety of ligands, including bacteria,
toxins, carbohydrates, and chromatin (Kirkpatrick et al., 2000).
The ability of these proteins to form big protein complexes that
can bind chromatin makes them intriguing in the context of early
human neural development.NPTX1 is expressed by adult hippo-
campal neurons (Cho et al., 2008) with no known function in em-
bryonic development. To assess the functional role of this gene
during neural induction, we made three lentiviral small hairpin
RNA (shRNA) constructs as previously described (Fasano et al.,
2007) and transduced hESCs. Two were successful in reducing
NPTX1 levels by mRNA and protein (Figures S1B–S1D), and len-
tiviral manipulation did not alter hESCpluripotencymarkerswhile
theyweremaintained in conditions favoring pluripotency (Figures
S1E and S1F). With the use of these verified constructs, clonal
hESC lines were established and differentiated toward the neural
lineage. At day 7, the cells were monitored for neural markers
PAX6 and SOX1 by quantitative RT-PCR (qRT-PCR) and immu-
nostaining. In addition to these markers, we also looked at the
early neuroectodermal markers GBX2 and SOX2 by qRT-PCR
(Patani et al., 2009). In the NPTX1 shRNA-treated cells, there
was a significant reduction in all neural markers compared with
the control (Figures 1C and 1D). Importantly, both the NPTX1
shRNA that was not effective at reducing NPTX1 levels and a
scrambled control did not alter neural induction as indicated by
PAX6 expression (Figures S1B and S1G). To verify NPTX1’s
role in other pluripotent lines, we differentiated bona fide induced
PSCs (iPSCs) generated in the lab (Figures S2A and S2B) towardCtheneural lineageandassessedNPTX1expression. Similar toour
findings in hESCs, we observed a transient increase in NPTX1
preceding the increase of the neural marker PAX6 (Figure S2C).
Using shRNA, we reduced the levels of NPTX1 in the iPSCs and
differentiated them toward the neural lineage. We found reduced
levels of PAX6 mRNA after 7 days, consistent with hESC results
(Figure S2D).
Inaddition to themarkeranalysis,wepickedhESC-derivedneu-
ral cells from each condition at day 9 and placed them in neuro-
sphere (NS)-forming conditions to identify neural progenitor cells
(NPCs) (Reynolds andWeiss, 1992). As expected, robust NS gen-
erationwas identified in thecontrol group,but theshRNAcondition
had significantly less NS generation, supporting the idea that
NPTX1 is important for neural induction (Figure 1E). Itwaspossible
that NPTX1 regulated the proliferation of already established pre-
cursors, and the reduction of NSs was the result of reduced NPC
proliferative capacity. To determine whether NPTX1 knockdown
was decreasing the proliferation of already specified precursors,
NSs were grown for 1 week, passaged, and then transduced
with a control or NPTX1 shRNA lentivirus. After 7 days of culture,
there was no difference in the number of NSs compared with the
control, suggesting that NPTX1 is important for neural induction,
but not for neural precursor proliferation (Figure 1F). In addition
toNSnumber,wealso lookedatNSsize, as smaller spheresmight
indicate a proliferation defect. In the NPTX1 shRNA cells, there
was no significant difference in NS size comparedwith the control
(Figure 1F). Finally, both control and shRNA hESCs were differen-
tiated toward the neural lineage, and at day 9 a cell-cycle analysis
was performed to rule out a proliferative defect. No significant dif-
ference was identified (Figure 1F).
It was also possible thatNPTX1 regulated the general differen-
tiation potential of hPSCs, and knocking it down would inhibit its
ability todifferentiate intoany lineage—not justneural. To test this,
we differentiated hESCS treated with NPTX1 shRNA toward
endodermal andmesodermal fates as previously described (Ken-
nedyetal., 2007;Nostroet al., 2011). For themesoderm,we found
that NPTX1 shRNA cells were able to give rise to Brachyury-
expressing cells (as determined by qRT-PCR) as well as KDR+
cells (as determined by flow analysis), indicating a mesodermal
fate (Figure 1G). Interestingly, the NPTX1 shRNA cells had higher
percentages of the mesodermal populations compared with the
control. Upon endoderm differentiation, NPTX1 shRNA cells ex-
pressed the endodermal marker SOX17 (by qRT-PCR) as well
as CXCR4+ cKit+ cells (by flow cytometry), indicating that both
the NPTX1 shRNA and control cells gave rise to endoderm (Fig-
ure1H).At no timepointmeasured foreithermesodermal orendo-
dermal differentiation did we find expression of PAX6, indicating
that neural differentiation had not occurred. These data suggest
that NPTX1 is upregulated prior to neural differentiation, and its
reduction leads to a deficit in neural induction from hPSCs.
To test whether Nptx1 regulates mouse neural induction, we
differentiated pluripotent mouse epiblast stem cells (mEpiSC)
(Tesar et al., 2007) to the neural lineage and looked at Nptx1
expression over the time course. Neural differentiation occurs
much faster in mice, with neural characteristics appearing be-
tween days 3 and 5 (Najm et al., 2011). To ensure that we could
identify a similar transcriptional event in mice, we looked as early
as 24 hr after differentiation for expression of Nptx1. In contrastell Reports 6, 724–736, February 27, 2014 ª2014 The Authors 725
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to what was observed in the human system,Nptx1 did not signif-
icantly increase until the neural lineage was already established
(day 4), suggesting that in mice it may not serve as an inducer of
neural fate (Figure S3A). To test NPTX1 functionally in this
context, we transduced mEpiSC with NPTX1 shRNA and differ-
entiated them to the neural lineage. Although a significant reduc-
tion in NPTX1 was observed, the ability to make neural cells was
not altered, as indicated by expression of the mouse neural
markers Sox2 and Nestin (Figure S3B). Therefore, these exam-
ples show that NPTX1 gene expression does not precede that
of neural identity in themouse, and suggest a possible difference
between the mouse and human systems.
NPTX1 Expression Enhances Neural Induction from
hPSCs
To test whether NPTX1 would enhance neural induction, we
used a lentiviral vector to force expression in hESCs. We differ-
entiated these cells, along with a control-transduced line, to the
neural lineage and analyzed them at four time points. As seen in
the control, NPTX1 expression peaked early, about the time the
pluripotency gene NANOG began to drop, and then rapidly
decreased before the neural markers PAX6 and SOX1 turned
on (Figure 2A). In the NPTX1 overexpression condition, NPTX1
levels were elevated from day 1, NANOG expression decreased
more rapidly, and PAX6 and SOX1 levels were increased earlier
and to a higher extent, as shown by qRT-PCR (Figure 2A). This
effect was confirmed by immunostaining that showed 57.2%
PAX6+ cells at day 5, compared with 24.6% in the control
(Figure 2B). Additionally, a dramatic reduction of NANOG was
seen by day 5 compared with the control, which still exhibited
robust staining (Figure 2B). These data show that NPTX1 accel-
erates pluripotency exit and neural differentiation from hESCs
under directed differentiation conditions.
We then examined whether NPTX1 alone would be able
to drive neural differentiation. NPTX1-transduced hESCs were
allowed to spontaneously differentiate in a base cell culture
medium without added growth factors. The sustained levels of
NPTX1 led to a more robust differentiation to PAX6+ cells
compared with the control and shRNA-treated cells (Figure 2C).
Additionally, Brachury and SOX17 levels were lower in the
NPTX1-overexpression condition compared with the control,
suggesting a preferential differentiation to the neural lineage (Fig-
ure 2C). The neural cells generated via NPTX1 overexpression
also expressed the neural markers SOX2 and Nestin (Figure 2D).Figure 1. NPTX1 Is Critical for Human Neural Induction
(A) Time course of NPTX1 expression during neural differentiation. qPCR sho
marker PAX6.
(B) Transient NPTX1 expression was confirmed at the protein level by ELISA.
(C) Time course of neural differentiation, showing a decrease in the expression o
shRNA-expressing cells.
(D) NPTX1 shRNA was shown to inhibit neural cell differentiation by immunostain
(E) Cells isolated at day 9 of neural differentiation from NPTX1 shRNA hESCs give
(F) hESCs were differentiated to neural cells, and at day 9 cells were picked and
difference in NS formation, NS size, or cell cycle (quantified on the right). Scale b
(G and H) NPTX1 shRNA hESCs were differentiated toward mesoderm or endode
an increase in mesoderm lineage cells in the NPTX1 shRNA-treated cells versus
chyury, whereas the endodermal marker Sox17 exhibited levels similar to the con
of cKit and CXCR4 in control and NPTX1 shRNA-treated cells.
All error bars are SEM. See also Figures S1–S3.
CNPTX1 is a secreted protein, and to determine whether it is
capable of autocrine or paracrine neural induction,we transduced
293 kidney cells withNPTX1 overexpression or control vector and
harvested the CM from each. To verify protein expression, we
added the CM to hESCs for 24 hr and fixed them for protein ana-
lyses. Using an NPTX1 antibody, we observed few NPTX1-posi-
tive cells in control CM-treated hESCs, whereas the NPTX1-CM
treated cells were now59%positive for NPTX1. To test the effects
of secreted NPTX1, hESCs were placed in both types of CM and
left to differentiate spontaneously for 7 days. Cells that were
treated with the control CM differentiated into few neural cells,
whereas those that received NPTX1 CM exhibited a neuroepithe-
lialmorphology (Figure 2E), robustly generated PAX6+ neural cells
(Figure 2F), and had lower levels ofNANOG (Figure 2G). This result
was dose dependent, as dilutions of NPTX1 CM resulted in
decreasing amounts of neural induction indicated by PAX6
expression. Interestingly, anything less than a 25% dilution did
not induce theneural lineage (Figure2H). Toconfirmthat thiseffect
wasspecific toNPTX1,wedifferentiatedhESCswithNPTX1CM in
the presence of anNPTX1 blocking peptide. In this context, neural
inductionwas severely inhibited (Figure 2H). In addition,we added
NPTX1 CM toNPTX1 shRNA differentiating hESCs and were able
to rescue the loss of neural cells (Figure 2I). These data suggest
thatNPTX1alonecandriveneuraldifferentiation robustly inhESCs
without the addition of other exogenous factors.
To test the strength of NPTX1 for driving differentiation toward
neural lineages, we attempted to derive both endoderm and
mesoderm in the NPTX1-overexpressing cells. Using flow
cytometry and qRT-PCR, we found that NPTX1-overexpressing
cells were able to differentiate into both mesoderm and endo-
derm (Figures 3A and 3B). However, in both differentiation proto-
cols, the NPTX1-overexpressing cells also gave rise to neural
cells, as measured by PAX6 expression. This result shows that
even when NPTX1-overexpressing cells are driven to produce
mesoderm and endoderm, they still produce a considerable
number of neural cells, indicating that NPTX1 exposure strongly
drives neural induction in hPSCs.
Loss of NPTX1 Maintains the Pluripotency Program
during Directed Neural Differentiation
To understand the mechanism of NPTX1-mediated neural
differentiation, we obtained high-resolution temporal gene-
expression profiles at five time points during the neural induction
protocol (Figure 4A). Global gene-expression studies werewed a transient increase in NPTX1 expression preceding that of the neural
f the key neural genes PAX6, GBX2, SOX2, and SOX1 by qRT-PCR in NPTX1
ing for PAX6 (red) and GFP (green).
rise to fewer NSs (quantified on the right). Scale bar, 100 mm; *p < 0.05; n = 3.
transduced with control or NPTX1 shRNA lentivirus. After 7 days there was no
ar, 100 mm; *p < 0.05, **p < 0.001; n = 3.
rm. Flow cytometry examining differentiating cells for KDR expression showed
control cells. qRT-PCR for mesoderm showed increased expression of Bra-
trol. In addition, flow analysis for endoderm induction shows similar expression
ell Reports 6, 724–736, February 27, 2014 ª2014 The Authors 727
A B
l ort no
C
N
P
TX
1 
C
M
Phase
D
Control CM
E
Day 7 Spontaneous Diff
0
20
40
60
80
*slle
C
+6
X
A
P
%
egnah
C
dloF
0
1
2
3
4
5
PAX
6
NA
NO
G
0
2
4
6
Control
NPTX1 Over
0
20
40
60
80
100
NPTX1 shRNA
* *
**
*
**
Day 7 Spontaneous Diff
slle
C
+6
X
AP
%
egnah
C
dloF
Sox17 Brachyury PAX6 DAPI/NESTIN/SOX2
rev
O
1
XT
P
N
Day 7 10X Day 7 32XC
F
GFP/PAX6
Day 7 
NPTX1 CM
lortno
C
rev
O
1
XT
P
N
I
P
A
D
/
G
O
N
A
N
/
6
X
AP
Day 1 Day 5
D1 D3 D5 D7
0
10
20
30
50
150
250
*
*
PAX6
egnah
C
dloF
0.00
0.10
0.20
1.0
1.5
*
NANOG
D1 D3 D5 D7
0
50
100
150
200
*
*
SOX1
D1 D3 D5 D7
NPTX1
egnah
C
dloF
Control Over
G
0
10
20
30
*
* *
*
D1 D2 D3 D5
% Conditioned Media 
PA
X6
 F
ol
d 
C
ha
ng
e
I P
A
D
/
6
X
AP
I P
A
D
/
6
X
AP
Day 7
N
P
TX
1 
C
M
H
0 12.5 25 50 100 100 + 
Blocking Peptide
0
10
20
30
40
lortno
C
I]*
(legend on next page)
728 Cell Reports 6, 724–736, February 27, 2014 ª2014 The Authors
Brachyury
D0 D4 D5 D8
0
10
20
30
40
50
Fo
ld
 C
ha
ng
e
PAX6
D0 D4 D5 D8
0
5
15
20
25
30
35
40
0
20
40
60
80
En
do
de
rm
 (C
XC
R
4+
/c
-K
it+
)
A
Control
NPTX1 Over
Control
NPTX1 Over
PAX6
D0 D4 D6
0
1
2
3
4
Control
NPTX1 Over
SOX17
D0 D4 D6
0
2
4
6
8
10
20
40
60
80
100
Fo
ld
 C
ha
ng
e
Control
NPTX1 Over
B
M
es
od
er
m
 (K
D
R
+)
D4 D5D3 D6 D7
0
20
40
60
80
D2D1
Control
NPTX1 Over
D4 D5D3 D6 D7
Control
NPTX1 Over
Figure 3. NPTX1-Overexpressing Cells Give
Rise to Neural Cells when Differentiated to
Other Lineages
NPTX1-overexpressing (NPTX1 Over) cells were
differentiated toward mesodermal or endodermal
lineages using established protocols.
(A) NPTX1Over cells differentiated into mesoderm
lineage cells at a lower rate than control cells.
In addition, qRT-PCR showed lower levels of
Brachyury (mesoderm) and high levels of PAX6
(neural lineages), indicating that the NPTX1 Over
cells were still deriving a hefty population of neural
cells as well.
(B) NPTX1 Over cells differentiated to endodermal
cells, albeit at a lower rate compared with control
cells, as measured by CXCR4 and cKit positivity
using flow cytometry, and by SOX17 expression
measured by qRT-PCR. Once again, higher
expression of PAX6 was observed.
All error bars are SEM. See also Figure S1.carried out in three independent samples for each time point and
culture condition. We analyzed the data for genes with signifi-
cant changes in their expression profiles by regressing the
normalized expression values using polynomial least-squares
regression, and performing an ANOVA on the coefficients of
regression to identify genes with significant changes and at least
a 2-fold difference between their high and low expression over
the time course for each group. Genes with significant changes
were then divided into three groups: genes that changed in the
control and NPTX1 shRNA cells (Table S1), genes that were
unique to the control cells (Table S2), and genes that were
unique to the NPTX1 shRNA cells (Table S3). Approximately
2,100 genes changed in the control cells during this time course;
however, only 955 genes changed expression in the NPTX1
shRNA condition, and roughly 701 of those genes also changed
in the control condition (Figure 4B). For a global view of the
changes specific to each condition, we undertook an enrich-
ment analysis to find gene categories in which the genes thatFigure 2. NPTX1 Is Adequate for Human Neural Induction
(A and B) hESCs overexpressingNPTX1were differentiated toward the neural lineage, resulting in accelerated
(PAX6 and SOX1), as shown by (A) qRT-PCR (*p < 0.05, n = 3) and (B) immunocytochemistry. Scale bar, 10
(C) hESCs transducedwith control,NPTX1 shRNA, orNPTX1-overexpression viruses were spontaneously diff
were seen in the control and significantly fewer were seen in the shRNA condition, whereasNPTX1-overexpre
graph shows the percentage of PAX6+ cells in each condition. The right graph shows the mRNA levels of ge
endoderm; Brachyury, mesoderm; and PAX6, neural ectoderm). *p < 0.05, **p < 0.001, n = 3.
(D) The resulting neural cells also express SOX2 and NESTIN. Scale bars, 100 mm and 50 mm.
(E–G) NPTX1 CM from transduced fibroblasts can induce neural cells from hESCs.
(E) At 5 days after NPTX1 CM addition, neuroepithelial-like cells were observed along with emerging PAX6+
(F) By day 7, a significant number of the cells present are PAX6+. Scale bar, 200 mm.
(G) Quantification of PAX6+ cells and mRNA levels of NANOG and PAX6 in the CM experiment. *p < 0.05, n
(H) Quantification of theCMexperiment showing that increasing levels of CM result in increasedPAX6 levels, a
(I) The NPTX1 CMwas added toNPTX1 shRNA hESCs andwas able to rescue the neural induction deficit whe
shRNA cells, PAX6 marks neural cells. Scale bar, 200 mm.
All error bars are SEM. See also Figures S1 and S6.
Cell Reports 6, 724–736,were unique to either the control or
NPTX1 shRNA cells were enriched.
Notably, Gene Ontology (GO) categoriesdealing with development of various tissues and cell differentia-
tion, including neural and brain development, were greatly en-
riched in the control cells, whereas in the NPTX1 shRNA cells,
these categories were either not enriched or were depleted (Fig-
ure 4C; Tables S4 and S5). Furthermore, the NPTX1 shRNA
expression profile showed enrichment for genes involved in plu-
ripotency (Table S6) when compared with the control expression
profile. In particular, genes such as OCT-4 and E-Cadherin failed
to reduce over time as they do in control hESCs during neural
differentiation. This was confirmed by qRT-PCR (Figure 4D).
Among the transcripts that were decreased in NPTX1 shRNA-
treated versus control cultures at day 7 of differentiation, we
found genes associated with neural development (e.g., PAX6
and EMX2; Table S2), as confirmed by qRT-PCR (Figure 4E).
Together, these data confirm our previous experiments showing
that NPTX1 shRNA reduces neural lineage commitment from
hESCs, and suggest that NPTX1 is a critical regulator of plurip-
otency versus neural commitment.pluripotency exit (NANOG) and neural commitment
0 mm.
erentiated in a KSR basemedium. Few PAX6+ cells
ssing cells robustly generated PAX6+ cells. The left
nes associated with all three germ layers (SOX17,
cells.
= 3.
nd the rescue using the blocking peptide (*p < 0.05).
n these cells were differentiated. GFP is amarker of
February 27, 2014 ª2014 The Authors 729
D
ay
 0
D
ay
 2
D
ay
 3
D
ay
 5
D
ay
 7
H1 Controls NPTX1 shRNA
D
ay
 0
D
ay
 2
D
ay
 3
D
ay
 5
D
ay
 7
S
am
e
Ti
m
e 
of
 M
ax
im
um
D
a y
 0
D
a y
 2
D
a y
 3
D
a y
 5
D
ay
 7
D
ay
 0
D
ay
 2
D
ay
 3
D
ay
 5
D
ay
 7
H1 Controls NPTX1 shRNA
D
iff
er
en
tT
im
e 
of
 M
ax
im
um
Low High
Expression Relative to Day 0 (log2)
0 5 10 15 30 50
H1 Control NPTX1 shRNA
Z-Score
Ribosome
Embryonic Appendage
Morphogenesis
Chromatin binding
Cell Junction 
Organization
DNA Recombination
Eye Development
Forebrain
Development
Muscle Tissue
Development
Heart Development
Brain Development
CNS Development
Regulation of 
Cell Development
Regulation of 
Cell Migration
mRNA Processing
RNA Splicing
Positive Regulation of
Cell Activation
Cell Fate 
Commitment
Protein Kinase
Cascade
A
B
C
EnrichedDepleted
E
D1 D2 D3 D5 D7
0
50
100
150
200
250
D1 D2 D3 D5 D7
80
100
120
140
160
180
D1 D2 D3 D5 D7
80
100
120
140
160
180
D1 D2 D3 D5 D7
80
100
120
140
160
180
D1 D2 D3 D5 D7
0
50
100
150
D1 D2 D3 D5 D7
40
60
80
100
120
D1 D2 D3 D5 D7
60
70
80
90
100
110
D1 D2 D3 D5 D7
40
60
80
100
120
* *
* *
*
*
*
*
*
*
* * *
* *
*
*
* *
OCT4 DNMT3B
E-Cadherin CD9
PAX6 DACH1
EMX2 FABP7
lortno
Cf
OtnecreP
lort no
C f
Ot necr eP
l ort no
Cf
Ot necre P
l ortn o
C f
Ot necreP
1391 254701
H1 Control 
(2092) NPTX1 shRNA 
(955)
D
Figure 4. Expression Profiling Reveals that NPTX1 shRNA Cells Are Delayed in Pluripotency Exit
(A) Heatmaps showing the expression-level fluctuations of significantly changing genes in both control and NPTX1 shRNA cells over the time course. The
heatmaps on the left show genes with the same time of maximum (TOM) between the control andNPTX1 shRNA cells, and the heatmaps on the right show genes
with different TOMs.
(B) Venn diagram describing the number of genes that changed in each condition and their relation to each other.
(C) GO enrichment analysis of genes that changed significantly over the time course and were unique to either control or NPTX1 shRNA cells reveals a pattern of
enrichment for development categories in control cells and a lack of enrichment of those categories in the NPTX1 shRNA cells. Significant changes cross the
orange thresholds.
(D and E) Real-time PCR of a select set of hESC maintenance genes (D) and genes involved in neural differentiation (E) shows a clear difference between control
cells and the NPTX1 shRNA cells. *p < 0.05, n = 3.
All error bars are SEM. See also Tables S1, S2, S3, S4, S5, and S6.
730 Cell Reports 6, 724–736, February 27, 2014 ª2014 The Authors
NPTX1 Binds TDGF1 and Negatively Regulates Nodal
Signaling
To investigate NPTX1’s role in pluripotency, we looked for
pluripotency genes that uniquely changed in the control cells,
and identified TDGF1, an essential positive regulator of Nodal
signaling, which decreased in expression during the time course
(Figure 5A). Nodal-TDGF1 signaling activates SMAD2/3 and in
turn NANOG expression, maintaining hESC pluripotency
(James et al., 2005; Vallier et al., 2009), and loss of Nodal
signaling has been shown to be an essential signal for neural in-
duction (Patani et al., 2009; Smith et al., 2008). TDGF1 has been
identified both in the extracellular space, as a secreted protein,
and in glycosylphosphatidylinositol linked to the membrane,
where it interacts with the Nodal receptor. TDGF1 interacts
with ALK4, the Nodal receptor, to permit Nodal to bind to the
receptor complex, leading to SMAD2 phosphorylation (Yeo
and Whitman, 2001).
To understand how TDGF1 was affected by NPTX1 manipula-
tion, we first used qRT-PCR to look at TDGF1 expression along
the neural differentiation time course. We found that, compared
with the control, TDGF1 expression was significantly higher
7 days after differentiation in the NPTX1 shRNA-treated cells
(Figure 5A). This was also true for SMAD2/3 and NANOG, sug-
gesting that NPTX1 may be regulating the Nodal pathway via
TDGF1 (Figure S4A). To confirm this, we looked next at the
NPTX1 amino acid sequence and compared it with key regula-
tors of the Nodal pathway. Interestingly, NPTX1 shares a striking
homology to LEFTY, a secreted antagonist of the Nodal
pathway. Lefty has been shown to modulate Nodal signaling
by binding to TDGF1, rendering Nodal signaling inactive (Chen
and Shen, 2004). To investigate whether NPTX1 works in a
fashion similar to that observed for LEFTY, we performed coim-
munoprecipitation (coIP) for TDGF1 and NPTX1 using the culture
media from differentiating hESCs. Indeed, NPTX1 could be
pulled down along with TDGF1, suggesting that NPTX1 binds
TDGF1 extracellularly, inhibiting its ability to bind to the Nodal re-
ceptor (Figure 5B). We next asked whether high levels of NPTX1
in the extracellular space would reduce the amount of TDGF1
present at the cell surface. CM from NPTX1-expressing cells
was harvested along with control media and added to hESCs
1 hr before fixation. Looking only at the cell surface, in the control
condition there were high levels of TDGF1 and low levels of
NPTX1 staining—a condition favorable to pluripotency. In the
conditions with NPTX1 CM, a much-reduced TDGF1 expression
was observed at the cell surface along with higher NPTX1 (Fig-
ure 5C). Finally, we made an NPTX1-His-tagged vector and
used it tomake aCMcontaining NPTX1-His.We applied thisme-
dium to hESCs for 1 hr and performed a coIP on the membrane
fraction of the lysed cells, andwere able to pull down TDGF1with
the NPTX1-His protein (Figure 5B). Together, these data suggest
that NPTX1 binds TDGF1 on the cell surface, as well as in the
extracellular space, providing a mechanism for how NPTX1
could modulate Nodal signaling.
To investigate this functionally, we looked at the nuclear
expression of SMAD2/3 in control and NPTX1-expressing
hESCs as a readout of active Nodal signaling. Undifferentiated
hESCs showed a high level of nuclear SMAD2/3 expression,
and during spontaneous differentiation, there were similarClevels of nuclear SMAD2/3 after 3 days. However, in the spon-
taneously differentiating NPTX1-expressing hESCs, there was
a dramatic decrease in nuclear SMAD2/3 expression after
3 days (Figure 5D). The same was observed for NANOG
expression (Figure S4B). These data suggest that NPTX1 mod-
ulates the Nodal pathway and the downstream pluripotency
program. To further verify whether TDGF1 is involved in
NPTX1-mediated neural induction, we added a TDGF1 block-
ing antibody into the NPTX1 shRNA condition. When TDGF1
was blocked, neural induction could proceed normally in the
NPTX1 shRNA cells, suggesting that NPTX1 increases neural
induction in part by binding TDGF1 and reducing Nodal
signaling (Figure 5E).
NPTX1 Expression Reduces BMP signaling
Secreted proteins expressed during development have been
shown to inhibit multiple signaling pathways. Cerberus is a
secreted protein that has been shown to inhibit both the Nodal
and BMP pathways (Piccolo et al., 1999). The directed neural dif-
ferentiation paradigm used in this study employs both TGF-b and
Noggin blockers, because it was originally shown that blocking
only TGF-b was not sufficient to drive neural commitment
(Chambers et al., 2009). Although TDGF1 works to enhance
Nodal signaling, it has been shown that Nodal itself can
bind up BMPs and thus lower BMP signaling (Yeo and Whitman,
2001). Because NPTX1 depletes available TDGF1 in the extra-
cellular space and cell surface, it seemed plausible that the
excess Nodal could now dampen BMP signaling. To test
whether NPTX1 expression can reduce BMP signaling, we em-
ployed the dual SMAD protocol to generate neural cells. In one
condition, we substituted NOGGIN for a TDGF1 blocking anti-
body to see whether TDGF1 loss could result in robust neural dif-
ferentiation. As a positive control for BMP signaling, one group
was treated with high levels of BMP7. After 7 days of differenti-
ation, we looked at neural marker expression and SMAD1 levels
(Figures 6A and 6B). As expected, the dual SMAD inhibition led
to robust PAX6 expression and negligible levels of pSMAD1.
hESCs treated with BMP7 or SB431542 (TGF-b antagonist)
alone gave rise to few PAX6 cells and exhibited high pSMAD1
levels. When SB431542 was combined with the TDGF1 blocking
antibody, robust PAX6 expression was observed along with
low levels of SMAD1. Finally, the TDGF1 blocking antibody alone
gave high PAX6 expression and lowered SMAD1 levels similar
to those observed with dual SMAD inhibition and NPTX1
overexpression. Together, these data indicate that NPTX1 in-
creases neural induction in part by reducing BMP signaling via
TDGF1 regulation.
DISCUSSION
Our study implicates a role for the pentraxin family of proteins
in regulating human nervous system development. Although
functional studies of NPTX1 in the adult mouse brain have
linked it to regulating synaptic transmission, no evidence for
it regulating neural development has been shown. Interestingly,
an Nptx1 null mouse was made in a previous study and no
neural induction deficits were identified (Bjartmar et al.,
2006). Our data show that as mouse PSCs differentiate,ell Reports 6, 724–736, February 27, 2014 ª2014 The Authors 731
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Figure 5. NPTX1 Binds TDGF1, Blocking Nodal Signaling to Induce Neurectoderm
(A) Upon neural differentiation, TDGF1 expression is rapidly downregulated, but this is abolished in the NPTX1 shRNA condition. *p < 0.05, n = 3.
(B) Using coIP, we were able to show that in spontaneously differentiating hESCs, NPTX1 can bind TDGF1 in the extracellular space. Using His-tagged NPTX1
media, we were also able to demonstrate that NPTX1 binds membrane-bound TDGF1 by coIP as well.
(C) Cells were treated with either control media or NPTX1 CM for 1 hr and stained for TDGF1 or NPTX1.
(D) Overexpression of NPTX1 leads to a rapid loss of nuclear SMAD2/3 upon differentiation. Scale bar, 50 mm.
(E) The addition of TDGF1 binding antibody rescues the neural differentiation deficit seen in the NPTX1 shRNA condition. Scale bar, 200 mm.
All error bars are SEM. See also Figures S4 and S5.NPTX1 is not expressed until neural markers appear, whereas
in humans, NPTX1 expression precedes the expression of neu-
ral markers. Additionally, knockdown of NPTX1 in mEpiSCs did
not affect their ability to induce neural cells. The discrepancy
between the mouse and our human data could be due to
many factors. First, NPTX1 could have different functions in732 Cell Reports 6, 724–736, February 27, 2014 ª2014 The Authorsmice and humans. Recently, a study revealed that the first
marker to be expressed in the human neural plate is PAX6,
not SOX1, whereas the opposite is true in mice, with Sox1 pre-
ceding the expression of Pax6 (Zhang et al., 2010). This finding
suggests that the beginning of neural commitment is different
in mice compared with humans, raising the possibility that
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Figure 6. NPTX1 Indirectly Dampens BMP Signaling
(A) hESCs were driven to differentiate by (1) the Chambers et al. (2009)
protocol, (2) TDGF1 blocking antibody (TDGF1-Ab) + SB431542, (3) TDGF1-
Ab, (4) NPTX1 overexpression, (5) BMP7 (control), and (6) SB431542. Cells
were then examined for PAX6 and SMAD1 expression by immunofluores-
cence. TDGF1-Ab demonstrated results similar to those obtained by NPTX1
overexpression and the Chambers et al. neural differentiation protocol. In
addition, TDGF1 blocking antibody is a reasonable substitute for Noggin
to inhibit BMP signaling, as measured by SMAD1 in the Chambers et al.
protocol. SB431542-alone-treated cells and BMP7-treated cells showed no
PAX6+ cells.
(B) Cells from each condition stained for PAX6 and SMAD1.
All error bars are SEM.NPTX1’s role in neural development might be confined to the
human system. Another possible explanation for the differ-
ences revealed by NPTX1 shRNA knockdown compared with
the Nptx1 knockout is that the knockout mouse has developed
compensatory mechanisms that enable neural development to
proceed normally. The shRNA studies reveal the effects of
acute gene loss, which do not allow a substantial amount ofCtime for a compensatory mechanism to develop. Previous
studies have shown differences in the role of proteins using
knockout versus shRNA (Blagosklonny, 2004; Fasano et al.,
2007). More studies comparing NPTX1’s role in mouse versus
human neural induction need to be carried out before concrete
conclusions can be made.
An important finding in our study is NPTX1’s dual mecha-
nism of action. Classically, it was shown that blockade of
both Activin/Nodal and BMP signals was necessary for neural
induction (Casellas and Brivanlou, 1998). This was mimicked in
a later study with hESCs using dual SMAD inhibition (Cham-
bers et al., 2009). In this study, when the BMP antagonist
NOGGIN was omitted, trophectoderm (a BMP-dependent line-
age) was generated as opposed to neural cells. However,
some reports in the literature suggest that blockade of only
the Activin/Nodal component is enough to enhance neural dif-
ferentiation from hESCS (Patani et al., 2009). The inconsistency
in these results might lie in the culture medium used in the two
studies. The former study used a medium containing the sup-
plement knockout serum replacement (KSR), whereas the
latter used a very defined medium with no KSR. There have
been studies looking specifically at the cell-signaling effects
of media containing KSR, and it was found to have a strong
BMP component (Xu et al., 2005). When hESCs are differenti-
ated in an environment where basal BMP signaling is higher,
blockade of this signal might be required for neural commit-
ment to proceed. In the dual SMAD protocol, the Nodal signal
is blocked by the drug SB43152, which prevents ALK4 phos-
phorylation and thus signal transduction. However, this drug
does not prevent the Nodal ligand from binding its receptor.
Our data show that NPTX1 reduces Nodal signaling by binding
to a coreceptor, TDGF1. Therefore, NPTX1 does not employ
the same method as SB431542 to block signaling. TDGF1
and Nodal bind in the extracellular space and then move to
the membrane or bind at the cell surface for signal transduc-
tion. If less TDGF1 is present, less Nodal will be at the receptor
and it will be free to perform other functions, such as binding
to BMPs and preventing receptor activation (Yeo and Whitman,
2001).
Interestingly, when the NPTX1 shRNA hESCs were differenti-
ated into the mesoderm lineage, a significant increase of meso-
dermal cells was identified. Mesoderm is a BMP-dependent
lineage, and this finding fits with the idea that NPTX1 expres-
sion will decrease BMP signaling due to a loss of TDGF1.
When NPTX1 levels are reduced, the Nodal-TDGF1 signaling
cascade is enhanced, allowing for less available Nodal to
bind to BMPs. Along the same lines, it has been shown that
dual SMAD blockade leads to commitment of neural cells
with an anterior identity (Chambers et al., 2009), whereas
blocking only the Activin/Nodal component converts neural
cells to a posterior identity (Patani et al., 2009). When neural
cells are generated by NPTX1 expression, they express
markers such as OTX2 and FOXG1 (Figure S5) just like cells
derived by dual SMAD inhibition, thus confirming the idea
that NPTX1 blocks both Nodal and BMP signals via TDGF1
inhibition.
Anterior neural cells are generated first in vivo and in vitro,
and we wondered whether this could somehow be encoded byell Reports 6, 724–736, February 27, 2014 ª2014 The Authors 733
NPTX1. To test this, we used a modified dual SMAD inhibition
protocol to generate a posterior neurectoderm and looked at
NPTX1 in this process. Just as in the anterior protocol, NPTX1
was expressed at the same time during the posterior differentia-
tion protocol (data not shown). This finding suggests that NPTX1
expression is specific to neural induction and does not confer
anterior identity to the neural cells. It will be interesting to inves-
tigate the key transcriptional events responsible for anterior
versus posterior patterning.
Regulation of the choice between pluripotency and differen-
tiation requires a delicate balance of signals that must be
tightly regulated. A recent study highlighted this point by look-
ing at how Activin/Nodal signaling can regulate both pluripo-
tency and endodermal differentiation (Brown et al., 2011).
Data from our study indicate that NPTX1 reduces Nodal
signaling and in turn pluripotency genes such as NANOG. It
is worth noting that we identified NPTX1 by using dual
SMAD inhibition for 3 days, and therefore NPTX1 expression
may be secondary to pluripotency exit and work by enhancing
an already present Nodal blockade while dampening BMP
signaling. Because signals in development are transient,
NPTX1 may be one of the first downstream effectors of neural
induction ultimately leading to neural lineage commitment.
Interestingly, when hESCs are left to spontaneously differen-
tiate by fibroblast growth factor 2 (FGF-2) withdrawal, neural
cells are generated at a low frequency. In this paradigm,
NPTX1 expression still turns on, albeit at a much a lower level
than when directed to the neural lineage (data not shown).
Also, in the hESC control cell line, exogenous dual SMAD in-
hibition after day 3 does not result in increased PAX6,
whereas in the NPTX1 knockdown line, the trend is an in-
crease in PAX6 when dual SMAD is added for longer than
3 days. This difference could be attributed to the lack of
endogenous regulation in the NPTX1 knockdown line. Neural
conversion is completely dependent upon the exogenous
dual SMAD block; thus, the more the signal is present, the
more neural induction is achieved, albeit always at lower
levels compared with the control (Figure S6). These data sug-
gest that a critical level of NPTX1 expression might be needed
to drive a complete neural conversion from hPSCs. This is
also echoed in our dose-response CM experiment showing
that after 3-fold dilution, neural induction is no longer
achieved.
In conclusion, we have identified a member of the pentraxin
protein family, NPTX1, as a critical regulator of neural lineage
commitment from hPSCs. We propose a model in which plurip-
otency exit leads to the expression and secretion of NPTX1,
which then binds and inhibits TDGF1 in the local environment.
The result of this action maintains a loss of Nodal and BMP
signaling, leading to neural differentiation. Our data provide
mechanistic insight into the endogenous regulators of human
nervous system commitment, as well as a method for deriving
neural cells from hPSCs with minimal cytokine and drug expo-
sure. In addition, because of its rapid expression profile during
neural differentiation, NPTX1 may be used in combination with
other methods (Bock et al., 2011; Boulting et al., 2011) to help
predict the ability of hPSC lines to differentiate toward the neural
lineage.734 Cell Reports 6, 724–736, February 27, 2014 ª2014 The AuthorsEXPERIMENTAL PROCEDURES
Cell Culture Conditions
hESCs (WA-09, passages 30–45), (WA-01, passages 35–45), and iPSC line 42
were cultured on mouse embryonic fibroblasts (MEFs; Global Stem) plated at
12–15,000 cells/cm2 in Dulbecco’s modified Eagle’s medium/F12, 20% KSR
(GIBCO), 0.1 mM b-mercaptoethanol, NEAA (GIBCO), and 10 ng/ml FGF-2
(R&D). For some cultures, hESCs were maintained using StemBeads FGF-2
(StemCulture). Cells were passaged using 6 U/ml of dispase in hESC media,
washed, and replated at a dilution of 1:10.
Neural Induction
Feeder-free neural induction was carried out as previously described (Cham-
bers et al., 2009). Briefly, hPSC cultures were disaggregated using Accutase
for 20 min, washed with hPSC media, and preplated on gelatin for 1 hr at
37C in the presence of ROCK inhibitor to remove MEFs. The nonadherent
hPSCs were washed and plated at a density of 20,000 cells/cm2 on Matrigel
(BD)-coated dishes in MEF conditioned hESC media (CM) spiked with
10 ng/ml of FGF-2 and ROCK inhibitor. The next day, the ROCK inhibitor
was withdrawn and the hESCs were allowed to expand in the CM for 3 days
or until they were nearly confluent. The initial differentiation media conditions
included KSR media with 10 nM TGF-b inhibitor (SB431542; Tocris) and
500 ng/ml of Noggin (R&D) or LDN 193189 (STEMGENT). Upon day 5 of differ-
entiation, increasing amounts of N2 media (25%, 50%, and 75%) were added
to the KSR media every 2 days while maintaining 500 ng/ml of Noggin and
TGF-b inhibitor. For TDGF1 antibody (ABCAM) experiments, antibody was
added at 1 mg/ml.
Lentiviral Constructs
A third-generation lentiviral vector (Lois et al., 2002) was modified to express
NPTX1 shRNAs from the H1 promoter as previously described (Fasano
et al., 2007). A list of the shRNA sequences is provided in the Supplemental
Experimental Procedures. For overexpression, the NPTX1 open reading frame
(ORF) was cloned by PCR using a bacterial clone template (Open Bio-Sys-
tems). The ORF was then placed into a lentiviral vector coexpressing GFP
(SBI Biosciences). Viral particles were generated as previously described
(Fasano et al., 2007).
Molecular Analyses
Total RNA was extracted using the RNeasy kit and DNase I treatment (-
QIAGEN), and reverse transcribed (QuantiTect; QIAGEN). For qRT-PCR, Taq-
man probes (ABI) were used according to the manufacturer’s protocols and
run on a Realplex2 system (Eppendorf). Normalized Ct values were calculated
as previously described (Fasano et al., 2010). Details regarding the microarray
methods can be found in the Supplemental Experimental Procedures. The mi-
croarray CEL files have been submitted to Gene Expression Omnibus (GEO;
GSE34551).
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde, permeabilized with Triton X-100-
containing buffer, and stained with primary antibodies (a list of the antibodies
used is provided in Supplemental Experimental Procedures). Appropriate
fluorescent-labeled secondary antibodies (Molecular Probes) and DAPI coun-
terstaining was used for visualization.
ACCESSION NUMBERS
The microarray CEL files have been submitted to GEO under accession num-
ber GSE34551.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and six tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.01.026.
AUTHOR CONTRIBUTIONS
N.B. performed microarray analysis, all biochemical assays, and FACS
analyses, and assisted with data interpretations and writing of the manuscript.
S.E.H. maintained hESC lines, performed neural differentiations and
qRT-PCR, and assisted with data interpretation and editing of the manuscript.
S. Le generated all lentiviral constructs and performed qRT-PCR. B.C. gener-
ated, characterized, and differentiated iPSC lines, and performed endoderm
and mesoderm differentiations. F.N. performed mouse epiblast stem cell ex-
periments. S. Lotz performed FACS analyses. A.P.M. helped maintain hPSC
lines. Q.W. assisted with IP and protein analyses. N.T. performed NPTX1 con-
trol experiments. P.J.T. supervised F.N. and helped with data interpretation
and manuscript preparation. C.A.F. designed and supervised execution of
the entire study, performed initial neural differentiations, assisted with data
interpretation and analysis, and wrote the manuscript.
ACKNOWLEDGMENTS
We thank Susan Goderie for technical assistance, Paul Worley for providing
the NPTX1 antibody, and Joseph Fasano, Karen Kirchofer, and Sally Temple
for critical readings of the manuscript. This work was supported by grants
from the NYSTEM program (C024177 and C024298), NINDS (NS072434-
01A1), and the Regenerative Research Foundation.
Received: November 19, 2012
Revised: December 6, 2013
Accepted: January 17, 2014
Published: February 13, 2014
REFERENCES
Bjartmar, L., Huberman, A.D., Ullian, E.M., Renterı´a, R.C., Liu, X., Xu, W.,
Prezioso, J., Susman, M.W., Stellwagen, D., Stokes, C.C., et al. (2006).
Neuronal pentraxins mediate synaptic refinement in the developing visual
system. J. Neurosci. 26, 6269–6281.
Blagosklonny, M.V. (2004). Do cells need CDK2 and ... Bcr-Abl? Cell Death
Differ. 11, 249–251.
Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z.D., Ziller,
M., Croft, G.F., Amoroso, M.W., Oakley, D.H., et al. (2011). Reference Maps
of human ES and iPS cell variation enable high-throughput characterization
of pluripotent cell lines. Cell 144, 439–452.
Boulting, G.L., Kiskinis, E., Croft, G.F., Amoroso, M.W., Oakley, D.H., Wainger,
B.J., Williams, D.J., Kahler, D.J., Yamaki, M., Davidow, L., et al. (2011). A
functionally characterized test set of human induced pluripotent stem cells.
Nat. Biotechnol. 29, 279–286.
Brown, S., Teo, A., Pauklin, S., Hannan, N., Cho, C.H., Lim, B., Vardy, L., Dunn,
N.R., Trotter, M., Pedersen, R., and Vallier, L. (2011). Activin/Nodal signaling
controls divergent transcriptional networks in human embryonic stem cells
and in endoderm progenitors. Stem Cells 29, 1176–1185.
Casellas, R., and Brivanlou, A.H. (1998). Xenopus Smad7 inhibits both
the activin and BMP pathways and acts as a neural inducer. Dev. Biol.
198, 1–12.
Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain,
M., and Studer, L. (2009). Highly efficient neural conversion of human
ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27,
275–280.
Chen, C., and Shen, M.M. (2004). Two modes by which Lefty proteins inhibit
nodal signaling. Curr. Biol. 14, 618–624.
Chng, Z., Teo, A., Pedersen, R.A., and Vallier, L. (2010). SIP1mediates cell-fate
decisions between neuroectoderm and mesendoderm in human pluripotent
stem cells. Cell Stem Cell 6, 59–70.
Cho, R.W., Park, J.M., Wolff, S.B., Xu, D., Hopf, C., Kim, J.A., Reddy, R.C.,
Petralia, R.S., Perin, M.S., Linden, D.J., and Worley, P.F. (2008). mGluR1/
5-dependent long-term depression requires the regulated ectodomain cleav-
age of neuronal pentraxin NPR by TACE. Neuron 57, 858–871.CD’Andrea, D., Liguori, G.L., Le Good, J.A., Lonardo, E., Andersson, O.,
Constam, D.B., Persico, M.G., and Minchiotti, G. (2008). Cripto promotes
A-P axis specification independently of its stimulatory effect on Nodal autoin-
duction. J. Cell Biol. 180, 597–605.
Fasano, C.A., Dimos, J.T., Ivanova, N.B., Lowry, N., Lemischka, I.R., and
Temple, S. (2007). shRNA knockdown of Bmi-1 reveals a critical role for
p21-Rb pathway in NSC self-renewal during development. Cell Stem Cell 1,
87–99.
Fasano, C.A., Chambers, S.M., Lee, G., Tomishima, M.J., and Studer, L.
(2010). Efficient derivation of functional floor plate tissue from human embry-
onic stem cells. Cell Stem Cell 6, 336–347.
Hemmati-Brivanlou, A., and Melton, D.A. (1994). Inhibition of activin receptor
signaling promotes neuralization in Xenopus. Cell 77, 273–281.
James, D., Levine, A.J., Besser, D., and Hemmati-Brivanlou, A. (2005).
TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripo-
tency in human embryonic stem cells. Development 132, 1273–1282.
Kennedy, M., D’Souza, S.L., Lynch-Kattman, M., Schwantz, S., and Kel-
ler, G. (2007). Development of the hemangioblast defines the onset of he-
matopoiesis in human ES cell differentiation cultures. Blood 109, 2679–
2687.
Kirkpatrick, L.L., Matzuk,M.M., Dodds, D.C., and Perin,M.S. (2000). Biochem-
ical interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor
binds to taipoxin and taipoxin-associated calcium-binding protein 49 via
NP1 and NP2. J. Biol. Chem. 275, 17786–17792.
Levine, A.J., and Brivanlou, A.H. (2007). Proposal of a model of mammalian
neural induction. Dev. Biol. 308, 247–256.
Lois, C., Hong, E.J., Pease, S., Brown, E.J., and Baltimore, D. (2002). Germline
transmission and tissue-specific expression of transgenes delivered by lentivi-
ral vectors. Science 295, 868–872.
Lonardo, E., Parish, C.L., Ponticelli, S., Marasco, D., Ribeiro, D., Ruvo, M., De
Falco, S., Arenas, E., and Minchiotti, G. (2010). A small synthetic cripto block-
ing Peptide improves neural induction, dopaminergic differentiation, and func-
tional integration of mouse embryonic stem cells in a rat model of Parkinson’s
disease. Stem Cells 28, 1326–1337.
Najm, F.J., Chenoweth, J.G., Anderson, P.D., Nadeau, J.H., Redline, R.W.,
McKay, R.D., and Tesar, P.J. (2011). Isolation of epiblast stem cells from pre-
implantation mouse embryos. Cell Stem Cell 8, 318–325.
Nostro, M.C., Sarangi, F., Ogawa, S., Holtzinger, A., Corneo, B., Li, X., Micallef,
S.J., Park, I.H., Basford, C., Wheeler, M.B., et al. (2011). Stage-specific
signaling through TGFb family members and WNT regulates patterning and
pancreatic specification of human pluripotent stem cells. Development 138,
861–871.
Patani, R., Compston, A., Puddifoot, C.A., Wyllie, D.J., Hardingham, G.E.,
Allen, N.D., andChandran, S. (2009). Activin/Nodal inhibition alone accelerates
highly efficient neural conversion from human embryonic stem cells and
imposes a caudal positional identity. PLoS ONE 4, e7327.
Piccolo, S., Agius, E., Leyns, L., Bhattacharyya, S., Grunz, H., Bouw-
meester, T., and De Robertis, E.M. (1999). The head inducer Cerberus is
a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature 397,
707–710.
Reynolds, B.A., and Weiss, S. (1992). Generation of neurons and astrocytes
from isolated cells of the adult mammalian central nervous system. Science
255, 1707–1710.
Smith, J.R., Vallier, L., Lupo, G., Alexander, M., Harris, W.A., and Peder-
sen, R.A. (2008). Inhibition of Activin/Nodal signaling promotes specifica-
tion of human embryonic stem cells into neuroectoderm. Dev. Biol. 313,
107–117.
Tesar, P.J., Chenoweth, J.G., Brook, F.A., Davies, T.J., Evans, E.P., Mack,
D.L., Gardner, R.L., and McKay, R.D. (2007). New cell lines from mouse
epiblast share defining features with human embryonic stem cells. Nature
448, 196–199.ell Reports 6, 724–736, February 27, 2014 ª2014 The Authors 735
Vallier, L., Reynolds, D., and Pedersen, R.A. (2004). Nodal inhibits differentia-
tion of human embryonic stem cells along the neuroectodermal default
pathway. Dev. Biol. 275, 403–421.
Vallier, L., Mendjan, S., Brown, S., Chng, Z., Teo, A., Smithers, L.E., Trotter,
M.W., Cho, C.H., Martinez, A., Rugg-Gunn, P., et al. (2009). Activin/Nodal sig-
nalling maintains pluripotency by controlling Nanog expression. Development
136, 1339–1349.
Weinstein, D.C., and Hemmati-Brivanlou, A. (1999). Neural induction. Annu.
Rev. Cell Dev. Biol. 15, 411–433.736 Cell Reports 6, 724–736, February 27, 2014 ª2014 The AuthorsXu, R.H., Peck, R.M., Li, D.S., Feng, X., Ludwig, T., and Thomson, J.A. (2005).
Basic FGF and suppression of BMP signaling sustain undifferentiated prolifer-
ation of human ES cells. Nat. Methods 2, 185–190.
Yeo, C., and Whitman, M. (2001). Nodal signals to Smads through Cripto-
dependent and Cripto-independent mechanisms. Mol. Cell 7, 949–957.
Zhang, X., Huang, C.T., Chen, J., Pankratz, M.T., Xi, J., Li, J., Yang, Y., Lav-
aute, T.M., Li, X.J., Ayala, M., et al. (2010). Pax6 is a human neuroectoderm
cell fate determinant. Cell Stem Cell 7, 90–100.
